The global endotoxin testing market is developing significantly with an expected CAGR of 8.5% from 2019 - 2029. Advances in technological processes are the key growth factor. For example: Limulus Amebocyte Lysate (LAL) test has been recommended by European and American pharmacopeia to identify bacterial endotoxins in the drugs through LAL test. This method was introduced in 1960s however, introduction on various kinds of reagents, kits and devices have simplified the process, thereby increasing the revenues and creating significant opportunities. The impact of covid 19 was severe in healthcare, though this market is not directly related to healthcare delivery institution, however, struggled due to pause on clinical trials across pharma and medical devices during the pandemic. The devices and drugs related to covid 19 were given utmost priority and further delays are expected for other range of devices and drugs awaiting FDA approvals. The report discusses impact of covid 19 over the market revenues and operational impact by geography in further detail.
Investment in Medical Devices Propelling Market Growth
The transition of medical device industry post the medical outsourcing has led to increased avenues in the developing economies as a result of increased and favorable public initiatives, regulations and increased market penetration for medical devices. Apart from widening scope of medical devices there has been tremendous growth and advances in automation of data entry, data management and reporting. Emerging technological advancement withrespect to laboratory testing has expanded the demand in Europe and Asia pacific. The key methods included in the endotoxin testing include turbidimetric method, gel clot method and custom method development. The key application areas include medical device manufacturing, pharmaceutical manufacturing, packaging manufacture and raw materials production. Advancements in products offering strong linearity and high sensitivity with reproducibility have led to higher revenues across the globe. Increasing developments withrespect to the entire healthcare industry and its infrastructure and emerging regulatory framework in developing economies such as China and India are expected to increase market revenues. However there is high cost involved in endotoxicin testing systems, apart from complexity in low endotixin recovery and stringent regulation in animal testing are expected to hamper the development in the market during the forecast period.
LAL Test Leads the Current and the Future Market
The endotoxin test uses methods such as Limulus amoeba cell lysate (LAL), rabbit pyrogen test (RPT), monocyte activation test (MAT), and recombinant factor C test, are deployed in the endotoxin testing. The LAL method has been used in pyrogen testing for over 30 years to detect endotoxins and is still expected to witness highest CAGR during the forecast period of 2019 to 2029. Monocyte activation testing is an in vitro method, is a comparatively newer method in the industry. Increasing Demand for animal-free testing methods and higher precision for LAL testing contributed to the growth of this segment. It has been observed that the LAL test continues to replace RBT and is recommended by pharmaceutical companies and international organizations. In addition, introduction of various testing methods, such as chromogenic endotoxin assay, gel clot endotoxin assay, and turbidimetric method are expected to expand the opportunities and market revenues. LAL test and tachypleus amebocyte lysate testing are evidencing upward curve due to increasing demand for biologics across the globe.
North America gained the largest share in 2019, followed by Europe in the endotoxin testing market in 2019, and the region is expected to remain strong during the 2019-2029. U.S. remains the key geographic region for endotoxin testing, the country offers a wide range of services, including scientific and manufacturing research. FDA-approved endotoxin testing techniques, increasing investment in pharmaceutical and biotechonology industries in APAC, Increasing adoption of advanced kits and systems have expanded the global market widely. The rapid growth in endotoxin testing market is therefore associated with large investments in the pharmaceutical industries by adopting high end testing systems for vaccines, biologics drug development, cancer research and other research programs. Increasing incidences of chronic disease in developed countries are expected to rise the focus on technological advancements during the forecast period, 2019 to 2029.
Key Players to Focus on R&D
Endotoxin testing is crucial in drug development and medical device development to contain the presence of pyrogenic substances. The key systems in the industry include ToxinSensor™ endotoxin discovery framework, PyroMAT™ System, Kinetic-QCLTM Kinetic Chromogenic LAL Assay, PYROGENTTM Gel Clot LAL Assay and others. The key players include Accugen Labs, Wako Chemicals USA, Inc., Charles River Laboratories, Inc., Pacific BioLabs, Sigma-Aldrich Co. LLC. Lonza, STERIS, Nelson Laboratories, LLC, Bio-Synthesis Inc, Biogenuix, Ellab A/S, GenScript Corporation, Thermo Fisher Scientific, Inc., Merck KGaA and others. The key strategy of these companies include R&D investment leading to increased FDA approvals of endotoxin testing systems and kits.
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.
This product will be delivered within 2 business days.
Investment in Medical Devices Propelling Market Growth
The transition of medical device industry post the medical outsourcing has led to increased avenues in the developing economies as a result of increased and favorable public initiatives, regulations and increased market penetration for medical devices. Apart from widening scope of medical devices there has been tremendous growth and advances in automation of data entry, data management and reporting. Emerging technological advancement withrespect to laboratory testing has expanded the demand in Europe and Asia pacific. The key methods included in the endotoxin testing include turbidimetric method, gel clot method and custom method development. The key application areas include medical device manufacturing, pharmaceutical manufacturing, packaging manufacture and raw materials production. Advancements in products offering strong linearity and high sensitivity with reproducibility have led to higher revenues across the globe. Increasing developments withrespect to the entire healthcare industry and its infrastructure and emerging regulatory framework in developing economies such as China and India are expected to increase market revenues. However there is high cost involved in endotoxicin testing systems, apart from complexity in low endotixin recovery and stringent regulation in animal testing are expected to hamper the development in the market during the forecast period.
LAL Test Leads the Current and the Future Market
The endotoxin test uses methods such as Limulus amoeba cell lysate (LAL), rabbit pyrogen test (RPT), monocyte activation test (MAT), and recombinant factor C test, are deployed in the endotoxin testing. The LAL method has been used in pyrogen testing for over 30 years to detect endotoxins and is still expected to witness highest CAGR during the forecast period of 2019 to 2029. Monocyte activation testing is an in vitro method, is a comparatively newer method in the industry. Increasing Demand for animal-free testing methods and higher precision for LAL testing contributed to the growth of this segment. It has been observed that the LAL test continues to replace RBT and is recommended by pharmaceutical companies and international organizations. In addition, introduction of various testing methods, such as chromogenic endotoxin assay, gel clot endotoxin assay, and turbidimetric method are expected to expand the opportunities and market revenues. LAL test and tachypleus amebocyte lysate testing are evidencing upward curve due to increasing demand for biologics across the globe.
North America Remains the Key Market
North America gained the largest share in 2019, followed by Europe in the endotoxin testing market in 2019, and the region is expected to remain strong during the 2019-2029. U.S. remains the key geographic region for endotoxin testing, the country offers a wide range of services, including scientific and manufacturing research. FDA-approved endotoxin testing techniques, increasing investment in pharmaceutical and biotechonology industries in APAC, Increasing adoption of advanced kits and systems have expanded the global market widely. The rapid growth in endotoxin testing market is therefore associated with large investments in the pharmaceutical industries by adopting high end testing systems for vaccines, biologics drug development, cancer research and other research programs. Increasing incidences of chronic disease in developed countries are expected to rise the focus on technological advancements during the forecast period, 2019 to 2029.
Key Players to Focus on R&D
Endotoxin testing is crucial in drug development and medical device development to contain the presence of pyrogenic substances. The key systems in the industry include ToxinSensor™ endotoxin discovery framework, PyroMAT™ System, Kinetic-QCLTM Kinetic Chromogenic LAL Assay, PYROGENTTM Gel Clot LAL Assay and others. The key players include Accugen Labs, Wako Chemicals USA, Inc., Charles River Laboratories, Inc., Pacific BioLabs, Sigma-Aldrich Co. LLC. Lonza, STERIS, Nelson Laboratories, LLC, Bio-Synthesis Inc, Biogenuix, Ellab A/S, GenScript Corporation, Thermo Fisher Scientific, Inc., Merck KGaA and others. The key strategy of these companies include R&D investment leading to increased FDA approvals of endotoxin testing systems and kits.
Historical & Forecast Period
This research report presents the analysis of each segment from 2019 to 2029 considering 2020 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segment are calculated for the forecast period from 2021 to 2029.
Key questions answered in this report
- What are the key market segments in current scenario and in the future by product categories
- What are the key market segments in current scenario and in the future by regions
- What is the key impact of Covid 19 over market revenues and market determinants in the medical aesthetics market?
- What are the primary and secondary macro and micro factors influencing the market growth currently and during the forecast period?
- What are the primary and secondary macro and micro factors deterring the market growth currently and during the forecast period?
- How to overcome the current market challenges and leverage the opportunities in each of the market segment?
- Who are the key players in the medical aesthetics market and what are their key product categories and strategies?
- What are the key strategies - mergers/acquisitions/R&D/strategic partnerships etc that companies are deploying to enhance market revenues and growth?
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Global Endotoxin Testing (ET) Market: Market Dynamics and Future Outlook
Chapter 4. Global Endotoxin Testing (ET) Market, by Product Type, 2019 - 2029 (US$ Mn)
Chapter 5. Global Endotoxin Testing (ET) Market, by Test Type, 2019 - 2029 (US$ Mn)
Chapter 6. Global Endotoxin Testing (ET) Market, by Application, 2019 - 2029 (US$ Mn)
Chapter 7. Global Endotoxin Testing (ET) Market, by Geography, 2019 - 2029 (US$ Mn)
Chapter 8. Company Profiles
Companies Mentioned
- ToxinSensor™ endotoxin discovery framework
- PyroMAT™ System
- Kinetic-QCLTM Kinetic Chromogenic LAL Assay
- PYROGENTTM Gel Clot LAL Assa. . The key players include Accugen Labs
- Wako Chemicals USA Inc.
- Charles River Laboratories Inc.
- Pacific BioLabs
- Sigma-Aldrich Co. LLC. Lonza
- STERIS
- Nelson Laboratories LLC
- Bio-Synthesis Inc
- Biogenuix
- Ellab A/S
- GenScript Corporation
- Thermo Fisher Scientific Inc.
- Merck KGa.